Table 5. Factors associated to cure in patients with strongyloidiasis in +REDIVI with available extra information (2009–2017).
| Overall (n = 705)a | Cure (n = 301) | Not cure (n = 404) | Univariate analysis (P value) |
Multivariate analysis (OR, 95%CI, and P value) |
|
|---|---|---|---|---|---|
| Mean age at diagnosis, years | 39.8 (SD 12.8, 2–88) | 40 (SD 12.5, 5–71) | 39.2 (SD 13.1, 2–88) | 0.132 | OR 1.01 (0.99–1.02), p = 0.132 |
| Gender, male | 344/705 (48.8%) | 130/301 (43.2%) | 214/404 (53%) | 0.010 | OR 0.64 (0.47–0.88), p = 0.007 |
| Presence of immunosuppressant condition | 50/705 (7.1%) | 27/301 (9%) | 23/404 (5.7%) | 0.094 | OR 1.37 (0.73–2.56), p = 0.314 |
| HTLV-1 co-infection (n = 152) | 7/152 (4.6%) | 4/105 (3.8%) | 3/47 (6.4%) | 0.677 | - |
| Presence of eosinophilia (n = 704) | 608/704 (86.4%) | 241/301 (80.1%) | 367/403 (91.1%) | <0.001 | OR 0.49 (0.30–0.78), p = 0.003 |
| Moderate/Severe eosinophilia (n = 704) | 268/704 (38.1%) | 107/301 (35.5%) | 161/403 (39.9%) | 0.234 | - |
| Definite diagnosis | 178/705 (25.2%) | 50/301 (16.6%) | 128/404 (31.7%) | <0.001 | OR 0.44 (0.30–0.64), p<0.001 |
| Presence of symptomsb | 122/705 (17.3%) | 63/301 (20.9%) | 59/404 (14.6%) | 0.028 | OR 1.42 (0.73–2.56), p = 0.094 |
| Treatment with ivermectin (n = 698) c | 644/698 (92.3%) | 285/299 (95.3%) | 359/399 (90%) | 0.009 | OR 2.34 (1.23–4.47), p = 0.009 |
NOTE. Data are reported as number (%) of patients or mean (SD, range).
a Patients with not enough information to establish the treatment outcome were withdrawn from the analysis.
b Patients in whom the main reason for consultation were not laboratory test alteration nor health screening.
c Patients were only analyzed when treated with a single drug (ivermectin or albendazole).